The effects of fenofibrate on cardiac function

Can adding fenofibrate to simvastatin improve exercise test findings in patients with dyslipidemia and coronary artery disease? a brief report

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012122411865N1

Enrollment

124

Registered

2013-02-25

Start date

2011-12-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease,dyslipidemia. Atherosclerotic heart disease,Pure hypercholesterolaemia,Pure hyperglyceridaemia,Mixed hyperlipidaemia,Other hyperlipidaemia,Hyperlipidaemia, unspecified

Interventions

Intervention 1: in intervention group simvastatin prescripted as standard therapy (20mg/d) as starting dose and if didn't improve lipid profile increased to 40mg/d after 1.5 month or 60mg/d after 3mo

Treatment - Drugs

in intervention group simvastatin prescripted as standard therapy (20mg/d) as starting dose and if didn't improve lipid profile increased to 40mg/d after 1.5 month or 60mg/d after 3month.and fenofibr

in control group simvastatin prescripted as standard therapy (20mg/d) as starting dose and if didn't improve lipid profile increased to 40mg/d after 1.5 month or 60mg/d after 3month for 12 monthes wit

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The inclusion criteria:patients diagnosed with constant CAD with positive Exercise Test Time (ETT); Total Cholesterol (TC)=200 mg/dl; Triglyceride (TG)=250 mg/dl; Low Density lipoprotein (LDL)=100 mg/dl; normal liver function test The inclusion criteria:patients diagnosed with constant CAD with positive Exercise Test Time (ETT); Total Cholesterol (TC)=200 mg/dl; Triglyceride (TG)=250 mg/dl; Low Density lipoprotein (LDL)=100 mg/dl; normal liver function test

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Exercise test. Timepoint: before and after intervention. Method of measurement: treadmill and changes in ECG.;Lipid profile. Timepoint: before intervention,1.5 month.3 month and after intervention(12month). Method of measurement: blood test.	—

Secondary

Measure	Time frame
Liver enzymes. Timepoint: before intervention,1.5 month,3 month,after intervention(12month). Method of measurement: blood test.;ECG. Timepoint: before and after intervention(12month). Method of measurement: electrocardiography device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmin Saburi

Baqiatallah University of Medical Sciences

aminsaburi@yahoo.com+98 21 8860 0067

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026